3 Akero employees smiling and conversing in a communal space

Our History

We have an established a track record of efficient and consistent achievement.

Our company was founded in 2017 with a vision of harnessing novel biology to develop therapeutics with a transformational, global impact on patients’ lives. We have made rapid progress toward that goal and pride ourselves on accurately projecting—and delivering—important milestones.
Stylized text for the year 2025

SYMMETRY Phase 2b Week 96 Readout

We announced preliminary topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX.

67
current employees
Stylized text for the year 2024
3
ongoing Phase 3 studies

HARMONY Phase 2b week 96 study readout reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX

Public follow-on offering with gross proceeds of approximately $366.9M

Stylized text for the year 2023

Public offering of $334.8M in net proceeds raised

SYMMETRY Phase 2b Expansion Cohort D readout showed safety and tolerability endpoints were met, and that adding EFX to GLP-1 therapy significantly improved noninvasive markers of MASH, offering benefit over GLP-1 therapy alone

SYMMETRY Phase 2b week 36 readout showed EFX treatment in F4 patients had a trend on fibrosis improvement, which was not statistically significant, and statistically significant results for MASH resolution, markers of liver injury and fibrosis, insulin sensitization and lipoproteins

Phase 3 SYMMETRY program initiated and dosed the first patients in two parallel, randomized, placebo-controlled Phase 3 trials: SYNCHRONY Histology evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic MASH, and SYNCHRONY Real-World assessing safety and tolerability of EFX in patients with noninvasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD)

Logo for SYMMETRY clinical study
Stylized text for the year 2022
Logo for HARMONY clinical study

HARMONY Phase 2b study readout showed statistical significance on both primary and secondary histology endpoints after 24 weeks in pre-cirrhotic (F2-F3) MASH

Upsized public follow-on offering with gross proceeds of approximately $230M

FDA breakthrough therapy designation for lead candidate EFX for the treatment of MASH

Stylized text for the year 2021

BALANCED expansion cohort readout showed potential for EFX to reverse fibrosis for cirrhotic MASH patients

Phase 2b HARMONY and SYMMETRY study initiation in pre-cirrhotic and cirrhotic MASH

32
employees and growing
Stylized text for the year 2020
A group meets for a presentation in a glass-walled conference room, while a woman talks on the phone in the background

Phase 2a BALANCED study readouts showed strongly positive and consistent improvements across multiple parameters

$216M upsized follow-on offering with cumulative financing surpassing $400M

New corporate headquarters completed in South San Francisco, CA

Stylized text for the year 2019

$106M upsized IPO just a year after first asset

First patient dosed in BALANCED study

Akero employees celebrate behind a podium at NASDAQ headquarters as confetti falls
Stylized text for the year 2018
7
employees

$65M Series A financing and Amgen license

$70M Series B/crossover financing

Manufacturing partnerships with Boehringer-Ingelheim and Vetter Pharma

A close-up of an Akero executive holding a pen and speaking with someone out of frame

We are led by a savvy team of biopharma industry veterans.